Over 50 Conservatives Vote Against Trump's Drug Pricing: 'Imports Socialist Price Controls' and 'Does Nothing'

A coalition of over 50 prominent conservative figures has voiced strong opposition to President Donald Trump's proposed 'most favoured nation' (MFN) drug pricing policy. They argue it would introduce socialist-style price controls and do little to solve America's healthcare problems.

The debate highlights a rift within the conservative movement, particularly over their ideals toward the President.

The Conservative pushback, is it still the GOP?

On Thursday, leaders from major free-market organisations sent a pointed letter to Congress. They criticised the Trump administration's effort to embed the MFN policy into law.

'Imports socialist price controls and values into our country,' they declared.

The signatories include familiar names like Grover Norquist, head of Americans for Tax Reform, and Stephen Moore, a former Trump economic adviser and co-founder of Unleash Prosperity Now.

The letter warns that implementing MFN would do more harm than good.

'While supporters of this proposal correctly identify the unique problems facing the American health care system, namely, wealthy countries paying artificially lower prices for prescription drugs than the US and the fact that this depresses innovation and inflates our costs, MFN would not solve these problems,' they wrote.

'In fact, it would exacerbate them'

Trump's MFN policy aims to lower drug prices by negotiating agreements with pharmaceutical companies. It intends to cap US prices based on the lowest prices found in other countries. The administration has already struck deals with 16 drug companies under this approach.

The president has been eager for Congress to make the policy permanent. A bipartisan group of lawmakers, including Reps. Ro Khanna, Anna Paulina Luna, Marcy Kaptur, and Andy Biggs, introduced legislation last year to codify the deals.

However, many conservatives see it differently. The signatories argue that the assumption MFN would lead to better negotiations is flawed.

'This belief is based on the flawed assumption that American manufacturers are not already fighting as hard as they can against foreign price controls,' they stated. They fear the policy could backfire severely.

The critics warn that adopting foreign-style price controls would severely hurt drug innovation.

'If the US implements the same price controls utilised by foreign countries, companies cannot expect to recuperate the R&D costs for the medicines they create,' the letter explained.

This could lead to fewer new drugs and even shortages.

'Reducing access to new cures and slowing innovation would harm American patients and the economy,' said Alfredo Ortiz, CEO of the Job Creators Network. The signatories express concern about the long-term impact on medical breakthroughs and the global competitiveness of U.S. pharmaceutical firms.

A rift among the Conservatives

The opposition from this coalition signifies a broader tension within the conservative camp. Many free-market advocates believe government intervention in drug pricing undermines innovation and free enterprise. Others worry about the potential for such policies to set a dangerous precedent, bringing socialist policies into the American healthcare system.

Meanwhile, President Trump remains committed. He argues that MFN will deliver fairer prices to Americans and curb foreign freeloading.

'We're negotiating deals to get the best prices for our people,' he has said.

But critics see the move as risky, potentially damaging the very innovation that makes America a global leader in medicine.

Beyond drug pricing, Trump's approach has raised eyebrows in some conservative circles. His moves, such as taking an equity stake in Intel and supporting broad global tariffs, have unsettled free-market advocates. These policies seem at odds with traditional conservative principles centred on free enterprise and limited government.

The debate over MFN exemplifies the ongoing challenge for Trump's administration to balance populist appeals with free-market values. Many conservatives fear that embracing policies like MFN could lead to a slippery slope of government overreach, undermining the innovation-driven economy.